Quick Search

 

 


 

 

Result Summary for 100310

Result Summary
Protocol ID: 100310
Clinical Study ID: RRL100310
Official Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)
Phase: Phase 3
Study Indications or Diseases:
  • Restless Legs Syndrome
Generic Name: ropinirole
Trade/Product Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara
Approved Drug Label: http://www.gsk.com/products.html
Results Summary: Click here to download result summary. Click here to download result summary.
Citations:

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.